Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.53 |
| ▸ | BCHE | P06276 | 3/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.45 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 7/20 | 0.44 |
| ▸ | RAB9A | P51151 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5619972 | 1.00 | MAOB (0.53) | MAOBBCHEPTPN1CYP1B1CYP1A1 | |
| SCHEMBL31233307 | 1.00 | MAOB (0.53) | MAOBBCHEPTPN1CYP1B1CYP1A1 | |
| SCHEMBL25288277 | 0.93 | MAOB (0.50) | MAOBBCHEPTPN1CYP1B1CYP1A1 | |
| SCHEMBL5619504 | 0.92 | BCHE (0.48) | MAOBBCHEPTPN1CYP1B1CYP1A1 | |
| SCHEMBL5619511 | 0.92 | BCHE (0.48) | MAOBBCHEPTPN1CYP1B1CYP1A1 | |
| SCHEMBL3064533 | 0.90 | ATM (0.50) | MAOBPTPN1CYP1B1CYP2D6MAPT | |
| SCHEMBL30383983 | 0.90 | ATM (0.50) | MAOBPTPN1CYP1B1CYP2D6MAPT | |
| SCHEMBL5620395 | 0.90 | CYP1B1 (0.53) | MAOBBCHECYP1B1CYP1A1MAPT | |
| SCHEMBL5620399 | 0.90 | CYP1B1 (0.53) | MAOBBCHECYP1B1CYP1A1MAPT | |
| SCHEMBL5619986 | 0.88 | MAPT (0.50) | MAOBPTPN1CYP1B1CYP1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4429763-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | Yewsavin, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-7276523-B2 | Aminopyridine derivatives as estrogen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276523-B2 | Aminopyridine derivatives as estrogen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276523-B2 | Aminopyridine derivatives as estrogen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-02 | — | — | US | disclosed |
| US-20040152688-A1 | Aminopyridine derivatives as estrogen receptor modulators | SMITHKLINE BEECHAM CORPORATION | 2004-08-05 | — | — | US | disclosed |
| WO-2002079163-A1 | AMINOPYRIDINE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152688-A1 | Aminopyridine derivatives as estrogen receptor modulators | ESR2, GPER1, ESR1 | MAOB 1367/4885BCHE 1905/4885PTPN1 2606/4885 |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | MAOB 1004/4885BCHE 588/4885PTPN1 1308/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | MAOB 2435/4885BCHE 465/4885PTPN1 1520/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | MAOB 2435/4885BCHE 465/4885PTPN1 1520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.